The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130
⏱️ 9 min read | After a turbulent past year, uniQure have shared encouraging news that the FDA has agreed their Phase I/II study data can serve as the basis for an application that could lead to the approval of AMT-130 in the US. Read more
First participant dosed in pioneering neural stem cell trial for Huntington’s disease
A new clinical trial for HD is underway. The first participant has been dosed in REGEN4HD, a study testing whether transplanting neural stem cells is safe as a potential treatment for HD. Read more
Evolving Needs, Evolving Care: Adapting Psychological Support Across Different Stages of Huntington’s Disease
⏱️ 9 min read | Huntington’s disease affects more than movement: it also has a major impact on mental health. Researchers explore why psychological care matters and how it needs to be adapted across each stage of HD. Read more
Sealing the gap: a case for slower, smarter DNA repair
⏱️ 7 min read | Your body assembles DNA like a team of workers who set and bond a pattern of tiles. A recent study shows that one special assistant might slow somatic CAG expansion and delaying HD onset. Read more
HDBuzz 2025 Annual Report: Here’s what you made possible
⏱️7 min read | In 2025, you helped us reach 329,000 people with independent, unbiased HD research news. Our 2025 Annual Report is here. Take a look at what we built together, and consider helping us keep going. Read more
Skyhawk reports encouraging 12-month results for oral Huntington’s disease drug SKY-0515
One year into treatment, SKY-0515 continues to lower huntingtin and shows encouraging trends with signs and symptoms of HD. A larger trial is enrolling to determine whether the drug truly slows HD progression Read more
EN 
ES 
IT 
DE 
FR 